From The Cutting Room Floor

  1. CSL Limited CEO Shares Insights Beyond Just How To Grow Revenue
    2/1/2017

    Being the head of any Big Pharma is bound to test an executive’s work-life balance. But when that Big Pharma is headquartered in Australia, and the company prides itself on being a “global operation,” maintaining any kind of work-life balance is a formidable task. “I’m not the poster child for how to strive for work-life balance,” admits Paul Perreault, CEO and managing director of CSL.

  2. 9 Questions With Takeda Oncology’s Chief Counsel And Head Of Patient Advocacy
    1/4/2017

    In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.

  3. What Will The Global Biopharmaceutical Industry Look Like In 2027: Trendsetter Series Part 4 of 4
    12/2/2016

    The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”

  4. Shire CEO and Novartis CMO Weigh In On Trends For 2017: Trendsetter Series Part 3 of 4
    12/2/2016

    The December 2016 issue of Life Science Leader magazine raised the bar in our 2017 Outlook feature article with participation from 13 trendsetters, including pharma leaders, payors, and a representative from the NIH. We hope you enjoy reading their thoughts in this supplement to the magazine’s December 2016 cover feature.

  5. How Biopharmas Are Addressing Key Trends For 2017: Trendsetter Series Part 2 of 4
    12/2/2016

    When Life Science Leader magazine asked for executive-level participation for the signature 2017 Outlook issue published in December 2016, we were overwhelmed with the response. This year’s feature article involved 13 executive thought leaders! In part two of this series, which is a supplement to the 2017 Outlook feature article, we pose the question, “What are you doing at your organization to address/capitalize on certain trends?” 

  6. What Trends Will Have The Biggest Impact On Biopharma In 2017: Trendsetter Series Part 1 of 4
    12/2/2016

    When Life Science Leader magazine asked executives to participate in our signature 2017 Outlook issue published in December 2016, the response was overwhelming. We gained participation from 13 life science leaders! But one of the challenges such a positive response creates is it makes it impossible to publish all of this great content.

  7. From Segregated Schools To Harvard — The Journey Of The President And CEO Of Otsuka Pharmaceutical
    10/3/2016

    Prior to my interview with William H. Carson, M.D., I noted that the president and CEO for Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) matriculated at Harvard University.  I was curious as to how Dr. Carson came to be enrolled at the institution. “Do you want the short story or long story?” he laughs.

  8. GSK President Of Vaccines Weighs In On Challenges Presented By Ebola And Zika
    9/1/2016

    Following Luc Debruyne’s participation in an educational session at this year’s BIO International Convention, the president of GSK Vaccines sat down with me to share his insights on the world of vaccines. During our conversation, (much of which was captured in the September 2016 feature article in Life Science Leader magazine), I asked Debruyne about some of the challenges faced by vaccine developers when it comes to viruses like Ebola and Zika.

  9. GSK’s Vaccines President Explains Vaccine Hesitancy
    9/1/2016

    Not long ago, a research team from the CDC fleshed out the measles activity in the United States. Much of the recent measles outbreak was linked to international travel and Disney Theme parks. While the threat may have come from imported infections, the reason the measles threat became a reality was largely the result of unvaccinated Americans. According to Luc Debruyne, president of GSK Vaccines and the subject of a feature article in Life Science Leader magazine’s September 2016 issue, the anti-vaccination movement is actually referred to as vaccine hesitancy, and is not just a U.S. but global phenomenon.

  10. The Backstory Behind What Hoos Hopes To Do At GSK
    9/1/2016

    While at Bristol-Myers Squibb (BMS), Axel Hoos, M.D., Ph.D. brought ipilimumab (the pioneering CTL-4 immuno-oncology drug) to market, essentially launching the field of immuno-oncology. So, I was curious as to why he decided to join GSK, where he currently serves as SVP therapeutic area head for oncology R&D and head of immuno-oncology. But to understand Hoos’ (the subject of Life Science Leader magazine’s September 2016 feature article) path to GSK, you need to first know why he went to BMS in the first place.